The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection

Gut

Volumn 65, Issue 8, 2016, Pages 1347-1358

  Abu Amara, Mahmoud ^a   Cerocchi, Orlando ^a   Malhi, Gurtej ^a   Sharma, Suraj ^a   Yim, Colina ^a   Shah, Hemant ^a   Wong, David K ^a   Janssen, Harry L A ^a   Feld, Jordan J ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASIAN; CANCER INCIDENCE; CANCER RISK; CHINESE UNIVERSITY HEPATOCELLULAR CARCINOMA MODEL; CHRONIC HEPATITIS B; CONTROLLED STUDY; FEMALE; FOLLOW UP; GUIDE WITH AGE AND GENDER HEPATOCELLULAR CARCINOMA MODEL; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NOMOGRAM 1 HEPATOCELLULAR CARCINOMA MODEL; NOMOGRAM 2 HEPATOCELLULAR CARCINOMA MODEL; NORTH AMERICAN; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ESTIMATION FOR HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B MODEL; SCORING SYSTEM; CANADA; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; INCIDENCE; LIVER FUNCTION TEST; LIVER NEOPLASMS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CANADA; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; ROC CURVE;

EID: 84930608536     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-309099     Document Type: Article

References (23)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
2. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-8.
3. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.
4. Sherman M, Bruix J, Porayko M, et al. Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012;56:793-6.
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
6. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8: 275-84.
7. Kim SS, Hwang JC, Lim SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223-33.
8. Singal AK, Salameh H, Kuo YF, et al. Meta-Analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013;38:98-106.
9. Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933-44.
10. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-47.
11. Abu-Amara M, Feld JJ. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? Semin Liver Dis 2013;33:157-66.
12. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5.
13. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
14. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437-44.
15. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8.
16. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015;62:363-70.
17. Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015;64:1289-95.
18. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
19. Kim WR, Berg T, Loomba R, et al. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocelluar carcinoma. J of Hepatol 2013;58:S19.
20. Hosaka T, Suzuki F, Kobayashi M, et al. Long-Term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
21. Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 2014;60:339-45.
22. Chang Y, Lairson DR, Chan W, et al. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. J Eval Clin Pract 2011;17:261-7.
23. Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012;5:49-54.